EFFICACY AND SAFETY OF LETERMOVIR FOR CYTOMEGALOVIRUS PROPHYLAXIS IN THORACIC ORGAN TRANSPLANTATION: A SYSTEMATIC REVIEW AND META-ANALYSIS (ACC 2026) - Jan 10, 2026 - Abstract #1467-222; Pres time: Mar 29, 2026; 11:00 AM - 12:00 PM; Location: Posters, Hall E; "The double-arm meta-analysis revealed no statistically significant difference in breakthrough CMV infection rates between LTV and Valganciclovir (VGC) (RR: 0.40; 95% CI: 0.09-1.68; P = 0.21). LTV prophylaxis demonstrates promising efficacy and safety in reducing breakthrough CMV infections, low-level viremia, and adverse events in TOT recipients. Its favorable safety profile, particularly in mitigating leukopenia, highlights its potential as an effective alternative to VGC. However, this evidence is limited by the small number of studies, heterogeneous populations, and relatively short follow-up periods, underscoring the need for larger randomized trials."
Retrospective data • Review • Bone Marrow Transplantation • Cytomegalovirus Infection • Hematological Disorders • Leukopenia • Transplantation
|
|
abdullah aldalati; Ayham Hussein; Bara Hammadeh; Bassel Alrabadi; Nihar Kanta Jena; West Virginia University; Camden Clark Medical Center; Parkersburg; WV; USA
|